SynBiotic is an investment vehicle that pursues an EU-focused buy-and-build approach. The core business of the platform company is the R&D of new cannabinoid and terpene-based solutions for the health issues of pain, sleep and anxiety.
More SynBiotic content >Investment summary
Management plans to utilise its experience in scaling profitable companies to accelerate SynBiotic’s strategy and become a leading platform company in the cannabinoids industry. It acquired SolidMind in June 20, followed by subsequent smaller deals, and we expect further deals as the platform grows. Increasing consumer acceptance of cannabinoids across a range of applications (from healthcare to wellbeing) ensures a huge target market. New product sources (both cannabinoids and plants) may enhance efficacy and lawful commercialisation. SynBiotic raised €6.3m of equity in December. Notwithstanding evident execution/ regulatory risk, SynBiotic seems cautiously rated at c 4x management’s projected FY21 revenue.
Content on SynBiotic
Sector |
|---|
|
Consumer
Access more Consumer content
|
Share price graph
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||